<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vedolizumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vedolizumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vedolizumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="95879" href="/d/html/95879.html" rel="external">see "Vedolizumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24932520"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Entyvio</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871770"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Entyvio</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F24891660"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Gastrointestinal Agent, Miscellaneous;</li>
<li>
                        Monoclonal Antibody;</li>
<li>
                        Monoclonal Antibody, Selective Adhesion-Molecule Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F25066769"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Prior to initiating treatment, all patients should be brought up to date with all immunizations according to current immunization guidelines.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7f75a24-c274-4715-807f-d302e2ab342d">Colitis, immune checkpoint inhibitor-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colitis, immune checkpoint inhibitor-induced (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For grade 2, 3, or 4 colitis with either high-risk endoscopic features on initial endoscopy examination or with persistent symptoms despite 3 days of corticosteroid therapy, consider adding vedolizumab to the treatment regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 300 mg at 0, 2, and 6 weeks and then (if needed) once every 8 weeks thereafter; use in combination with a corticosteroid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392','lexi-content-ref-34172516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="698502f2-8371-4f7b-b52e-f26b1c2278b7">Crohn disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 300 mg at 0, 2, and 6 weeks and then every 8 weeks thereafter. Discontinue therapy in patients who show no evidence of therapeutic benefit by week 14.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ</b> [Canadian labeling]: Maintenance: 108 mg once every 2 weeks beginning after at least 2 IV infusions; administer in place of next scheduled IV dose and then every 2 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed dose:</i> Administer next dose as soon as possible and then every 2 weeks thereafter.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e147f438-ac03-44c7-98c9-bf0acd598ea0">Ulcerative colitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 300 mg at 0, 2, and 6 weeks and then every 8 weeks thereafter. Discontinue therapy in patients who show no evidence of therapeutic benefit by week 14.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Maintenance: 108 mg once every 2 weeks beginning after at least 2 IV infusions; administer in place of next scheduled IV dose and then every 2 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed dose:</i> Administer next dose as soon as possible and then every 2 weeks thereafter.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991880"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989211"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Discontinue use with jaundice or signs/symptoms of hepatic injury.</p></div>
<div class="block doe drugH1Div" id="F25066770"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F58243963"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Infusion-related hypersensitivity and/or cutaneous reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion-related reactions</b> have been reported, including symptoms resembling <b>anaphylaxis</b>. Symptoms include flushing, <b>skin rash,</b> urticaria, <b>arthralgia</b>, myalgias, and <b>fever</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26336591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26336591'])">Ref</a></span>). Acute noncardiac chest pain has also been reported. Other cutaneous manifestations (eg, IgA-mediated leukocytoclastic vasculitis or Henoch-Schönlein purpura, nodular vasculitis, pyoderma gangrenosum) have been reported and may be delayed, occurring weeks to months after initiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26336591','lexi-content-ref-33048114','lexi-content-ref-29614303','lexi-content-ref-35949229','lexi-content-ref-32496114','lexi-content-ref-35134937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26336591','lexi-content-ref-33048114','lexi-content-ref-29614303','lexi-content-ref-35949229','lexi-content-ref-32496114','lexi-content-ref-35134937'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate:</i> Vedolizumab also contains polysorbate 80, which is a known excipient that can induce immediate hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33737254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33737254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Delayed reactions: </i>Unknown; dermatological-associated events may be triggered by the impact of vedolizumab on peripheral skin inflammatory cascades (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29614303']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29614303'])">Ref</a></span>); other infusion-related reactions may result from development of anti-vedolizumab antibodies, which have been detected in severe reactions including noncardiac chest pain during the infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35949229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35949229'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most infusion-related reactions have occurred within 2 hours of the completion of the infusion but can occur within minutes of the start of the infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35949229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35949229'])">Ref</a></span>). In general, cutaneous vasculitis and other cutaneous reactions typically occur within 7 to 10 days of the inducing factor but have been identified after several vedolizumab infusions were previously tolerated and can occur after weeks or months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33048114','lexi-content-ref-29614303','lexi-content-ref-35134937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33048114','lexi-content-ref-29614303','lexi-content-ref-35134937'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Some studies suggest the presence of anti-vedolizumab antibodies in patients with infusion reactions in the absence of detectable vedolizumab trough levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35949229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35949229'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Increased serum alanine aminotransferase</b> and <b>increased serum aspartate aminotransferase</b> (≥3 times the upper limit of normal) have been reported with vedolizumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36404891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36404891'])">Ref</a></span>). <b>Increased serum transaminases</b> are commonly encountered in patients with inflammatory bowel disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17100965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17100965'])">Ref</a></span>), while the incidence of vedolizumab-induced <b>hepatic injury</b> is rare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36404891','lexi-content-ref-33155638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36404891','lexi-content-ref-33155638'])">Ref</a></span>). Reported cases of vedolizumab-induced hepatic injury may present as mixed or cholestatic, and liver biochemistries tend to improve upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36404891','lexi-content-ref-34901448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36404891','lexi-content-ref-34901448'])">Ref</a></span>). Underlying liver diseases (eg, primary biliary sclerosis) must also be excluded if vedolizumab-induced hepatic injury is suspected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36404891','lexi-content-ref-34901448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36404891','lexi-content-ref-34901448'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; vedolizumab inhibits α4β7 integrin, selectively preventing gut specific signaling of T-lymphocytes and eosinophil migration and adhesion, which may increase peripheral eosinophilia commonly seen in allergic reactions such as immune-mediated hepatic injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36404891','lexi-content-ref-33155638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36404891','lexi-content-ref-33155638'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; range reported is 14 to 275 days after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36404891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36404891'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Previous injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36404891','lexi-content-ref-34901448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36404891','lexi-content-ref-34901448'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Current alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34901448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34901448'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (≥55 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34901448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34901448'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Progressive multifocal leukoencephalopathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Progressive multifocal leukoencephalopathy</b> (PML) is a neurological disorder characterized by severe disability that can be fatal and is caused by John Cunningham virus (JCV) in the setting of significant immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29668955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29668955'])">Ref</a></span>). Natalizumab has been linked to an increased risk of PML and has a similar mechanism of action to vedolizumab, therefore prompting concerns for evaluation and monitoring of PML in patients receiving therapy. Unlike natalizumab, vedolizumab targets a different subunit of integrin expressed on gut-homing T-lymphocytes and does not impact immune surveillance within the central nervous system (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29668955','lexi-content-ref-30635807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29668955','lexi-content-ref-30635807'])">Ref</a></span>). Cases of vedolizumab-associated PML have yet to be identified, and the risk remains theoretical and based on data from natalizumab exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29668955','lexi-content-ref-30635807','lexi-content-ref-29737503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29668955','lexi-content-ref-30635807','lexi-content-ref-29737503'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time related (delayed); related to the pharmacologic action (ie, monoclonal antibody targeting α4β7 integrin, a cell surface glycoprotein on B and T lymphocytes that binds to mucosal addressin cell adhesion molecule-1 on the intestinal vasculature) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26893500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26893500'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; occurs after 30 days of drug therapy (based on data from natalizumab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29668955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29668955'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy &gt;2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29668955','lexi-content-ref-29737503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29668955','lexi-content-ref-29737503'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior or concurrent immunosuppression during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29668955','lexi-content-ref-29737503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29668955','lexi-content-ref-29737503'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Positive JCV antibody identified prior to or during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29668955','lexi-content-ref-29737503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29668955','lexi-content-ref-29737503'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of blood cancers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29668955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29668955'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serious infections</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Although the immunosuppressive activity of vedolizumab is focused on gut specific pathways, use may be associated with an increased risk for developing <b>infection</b>; most reported infections included <b>upper respiratory tract infections</b> and <b>nasopharyngitis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33387667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33387667'])">Ref</a></span>). The risk of serious infections, requiring hospitalization, is like other anti-TNF agents based on recent pooled analyses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33387667','lexi-content-ref-35944832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33387667','lexi-content-ref-35944832'])">Ref</a></span>) and have resolved with treatment discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27296941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27296941'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to the pharmacologic action (ie, monoclonal antibody targeting α4β7 integrin, a cell surface glycoprotein on B and T lymphocytes that binds to mucosal addressin cell adhesion molecule-1 on the intestinal vasculature) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26893500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26893500'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prior anti-TNF use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26893500','lexi-content-ref-33387667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26893500','lexi-content-ref-33387667'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent narcotic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26893500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26893500'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26893500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26893500'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent corticosteroid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26893500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26893500'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33470695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33470695'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F25119219"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (6%; neutralizing: 3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (3%), skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (≥3 × ULN: &lt;2%), increased serum aspartate aminotransferase (≥3 × ULN: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (4%)<span class="lexi-table-link-container"> (<a aria-label="Infusion-Related Reaction table link" class="lexi-table-link" data-table-id="lexi-content-infusion-related-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infusion-related-reaction')">table 1</a>)</span><span class="table-link" style="display:none;">Infusion-Related Reaction</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infusion-Related Reaction" frame="border" id="lexi-content-infusion-related-reaction" rules="all">
<caption style="text-align:center;">
<b>Vedolizumab: Adverse Reaction: Infusion-Related Reaction</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Vedolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vedolizumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Crohn disease or ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,434</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">297</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (9%; including bruising at injection site, erythema at injection site, hematoma at injection site, rash at injection site, swelling at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (4%), limb pain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (4%), cough (5%), oropharyngeal pain (3%), sinusitis (3%), upper respiratory tract infection (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (9%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hematologic &amp; oncologic: Malignant neoplasm (excluding dysplasia and basal cell carcinoma)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis, cholestasis (Honap 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Peripheral eosinophilia (De Marco 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury (De Marco 2022), hepatitis (including toxic hepatitis) (Mascarenhas Saraiva 2020), increased serum bilirubin, increased serum transaminases (including increased serum alkaline phosphatase, increased gamma-glutamyl transferase) (De Marco 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (including anal abscess, sepsis, tuberculosis, salmonella sepsis, meningitis due to <i>Listeria monocytogenes</i>, giardiasis, cytomegalovirus disease [colitis])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Progressive multifocal leukoencephalopathy (in a patient with multiple risk factors [ie, HIV, CD4 count 300 cells/mm<sup>3</sup>, prolonged prior and concurrent immunosuppression]) (Loftus 2020)</p></div>
<div class="block coi drugH1Div" id="F24891662"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serious or severe hypersensitivity to vedolizumab or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Patients with active severe infections or opportunistic infections.</p></div>
<div class="block war drugH1Div" id="F25066758"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Therapy is not recommended in patients with uncontrolled, active, severe infections. If a patient develops a serious infection, consider discontinuing therapy. Use with caution in patients with a history of recurring severe infections.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should be brought up to date with all immunizations according to immunization guidelines before initiating therapy. Live vaccines should not be given concurrently unless the benefits outweigh the risks; there are no data on the secondary transmission of infection by live vaccines with vedolizumab. Non-live vaccines may be given concurrently.</p></div>
<div class="block foc drugH1Div" id="F24932521"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Entyvio: 108 mg/0.68 mL (0.68 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Entyvio: 300 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F24932519"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F25211461"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Entyvio Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $10,399.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Entyvio Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">108MG/0.68ML (per 0.68 mL): $3,743.96</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871771"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Entyvio: 108 mg/0.68 mL (0.68 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Entyvio: 108 mg/0.68 mL (0.68 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Entyvio: 300 mg (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F25066773"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 30 minutes. Do not administer by IV push or bolus. Following infusion, flush with 30 mL of sterile 0.9% sodium chloride injection or LR. Observe patients during infusion (until complete) and monitor for hypersensitivity reactions; discontinue if a reaction occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Allow pen to reach room temperature (30 minutes) after removing from refrigerator; do not warm in other ways or let sit in direct sunlight. Do not shake. Administer by SUBQ injection into front of thighs, abdomen (avoid area 2 inches around navel), or back of the upper arm; rotate injection sites. Do not inject into bruises, moles, scars, or damaged, hard, red, or tender skin. Initial use is recommended under supervision of physician; self injection may occur after proper training. Do not reuse prefilled pens; single use only.</p></div>
<div class="block meg drugH1Div" id="F25119218"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Entyvio: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761133s000lbl.pdf%23page%3D23&amp;token=2v6xD5Wb8omXM0MjeFaUWOtYiD7LwOfcHSKNGmBS64DKG1WGjpCEocYIjULkk%2FnGCznYvvpCwZX331o3Id7rCzGuRwYLO35FMWGeCC9ho%2Bzu7Ngouk%2BxreiIXfJ4UB0p&amp;TOPIC_ID=95501" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761133s000lbl.pdf#page=23</a></p></div>
<div class="block use drugH1Div" id="F24891643"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease:</b> Treatment of Crohn disease in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis:</b> Treatment of ulcerative colitis in adults.</p></div>
<div class="block off-label drugH1Div" id="F57596586"><span class="drugH1">Use: Off-Label: Adult</span><p>Colitis, immune checkpoint inhibitor-induced</p></div>
<div class="block cyt drugH1Div" id="F24958204"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F24958201"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-TNF Agents: May enhance the adverse/toxic effect of Vedolizumab.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Vedolizumab may enhance the adverse/toxic effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Travelers' Diarrhea and Cholera Vaccine: Vedolizumab may diminish the therapeutic effect of Travelers' Diarrhea and Cholera Vaccine.  Management: Administer travelers' diarrhea and cholera vaccine prior to initiation of therapy with vedolizumab.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53688068"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Biologics, such as vedolizumab, may be continued in patients with inflammatory bowel disease planning to become pregnant (Mahadevan 2019). Treatment algorithms are available for use of biologics in patients with Crohn disease who are planning a pregnancy (Weizman 2019). When treatment for inflammatory bowel disease is needed, serum levels of biologic therapy should be optimized prior to conception (Mahadevan 2019).</p></div>
<div class="block pri drugH1Div" id="F25066755"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Vedolizumab crosses the placenta (Flanagan 2020; Julsgaard 2021; Mahadevan 2021; Mitrova 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Vedolizumab is a humanized monoclonal antibody (IgG1). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009). Vedolizumab concentrations in cord blood and newborn serum are generally lower than those in the maternal serum at delivery (Flanagan 2020; Julsgaard 2021; Mahadevan 2021). In a study of 17 mother-infant pairs, vedolizumab serum concentrations were available in a subset of infants at 6 to 8 weeks of age (last intrapartum dose given at a median 30 weeks). Vedolizumab was measurable in the serum of 6 infants and not detected in the serum of 4 infants. Vedolizumab remained measurable in 1 infant at 12 weeks of age (Flanagan 2020). In a study of 43 mother-infant pairs, there were no infants exposed to vedolizumab in utero that had detectable serum concentrations at 6 months of age (Julsgaard 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Data related to the use of vedolizumab in pregnancy are available (Bar-Gil Shitrit 2019; Chambers 2021; Ghalandari 2022; Julsgaard 2017; Mahadevan 2017; Mitrova 2022; Moens 2019; Moens 2020; Sheridan 2017; Wils 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of vedolizumab may be altered. Maternal serum levels may decrease as pregnancy progresses due increased clearance; however, this may not be clinically significant (Flanagan 2020).</p>
<p style="text-indent:0em;margin-top:2em;">The safety of administering live vaccines to infants exposed to vedolizumab in utero is not known. Vaccination with live vaccines (eg, rotavirus vaccine) should be avoided for the first 6 months of life if exposure to a biologic agent occurs during the third trimester of pregnancy (eg, &gt;27 weeks' gestation) (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Inflammatory bowel disease is associated with adverse pregnancy outcomes including an increased risk of miscarriage, premature delivery, delivery of a low-birth-weight infant, and poor maternal weight gain. Management of maternal disease should be optimized prior to pregnancy. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">When treatment for inflammatory bowel disease is needed in pregnant patients, appropriate biologic therapy can be continued without interruption. Serum levels should be evaluated prior to conception and optimized to avoid subtherapeutic concentrations or high levels which may increase placental transfer. Dosing can be adjusted so delivery occurs at the lowest serum concentration. For vedolizumab, the final injection can be given 6 to 10 weeks prior to the estimated date of delivery (4 to 5 weeks before delivery if every-4-week dosing), then continued 48 hours' postpartum (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to vedolizumab is ongoing. Health care providers are encouraged to enroll patients exposed to vedolizumab during pregnancy in a pregnancy exposure registry. Information about the registry can be obtained by calling 1-877-825-3327.</p></div>
<div class="block brc drugH1Div" id="F25066757"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Vedolizumab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">In 2 studies, with a total of 10 lactating women, breast milk was sampled prior to and up to 14 days following a maternal dose. Vedolizumab was present at each time point evaluated. The highest concentrations occurred 3 to 7 days after the dose and were ≤1% of the maternal serum concentration. Breastfed infants were followed for up to 10 months and reached their developmental milestones (Julsgaard 2018; Lahat 2018); GI infections were not observed (Lahat 2018) and inactivated vaccines were administered without complication (Julsgaard 2018). A third study of 11 women also observed peak breast milk concentrations of vedolizumab to occur on days 3 to 4 following the maternal dose then decrease exponentially. Vedolizumab could be detected in breast milk in low levels up to 57 days after the infusion (Sun 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Vedolizumab was not detectable in the serum of 4 infants exposed in-utero and via breast milk. Vedolizumab was present in cord blood at birth, but not detectable in their serum at 3 months of age and until sampling stopped at 12 months of age. Vedolizumab breast milk concentrations were not evaluated in this study (Julsgaard 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">It is expected that any vedolizumab ingested via breast milk would be degraded in the infant GI tract and have minimal impact to the breastfed infant (Julsgaard 2018; Lahat 2018; Sun 2020). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother; however, available guidelines note maternal use of vedolizumab is considered compatible with breastfeeding (Mahadevan 2019).</p></div>
<div class="block mop drugH1Div" id="F25066775"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe patients during infusion (until complete) and monitor for hypersensitivity reactions; LFTs; tuberculosis screening according to local practice; signs/symptoms of infection; signs/symptoms of progressive multifocal leukoencephalopathy, including new onset or worsening of neurological signs and symptoms (eg, progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes); any new onset or worsening of neurological signs and symptoms</p></div>
<div class="block pha drugH1Div" id="F25066763"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vedolizumab is a humanized monoclonal antibody that binds to the alpha4beta7 integrin and blocks the interaction of alpha4beta7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. The interaction of the alpha4beta7 integrin with MAdCAM-1 has been implicated as an important contributor to the chronic inflammation that is a hallmark of ulcerative colitis and Crohn disease.</p></div>
<div class="block phk drugH1Div" id="F25066765"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~5 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: ~75%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~24 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: SUBQ: 7 days (range: 3 to 14 days).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F25233230"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Kynteles</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Entivio</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Entyvio</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30518410">
<a name="30518410"></a>Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. <i>J Immunother Cancer</i>. 2018;6(1):142. doi:10.1186/s40425-018-0461-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/30518410/pubmed" id="30518410" target="_blank">30518410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30920987">
<a name="30920987"></a>Bar-Gil Shitrit A, Ben Yaʼacov A, Livovsky DM, et al. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study [published online March 5, 2019]. <i>Am J Gastroenterol.</i> doi: 10.14309/ajg.0000000000000186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/30920987/pubmed" id="30920987" target="_blank">30920987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172516">
<a name="34172516"></a>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer</i>. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/34172516/pubmed" id="34172516" target="_blank">34172516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33737254">
<a name="33737254"></a>Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA Jr. Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. <i>J Allergy Clin Immunol Pract</i>. 2021;9(8):2968-2982. doi:10.1016/j.jaip.2021.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/33737254/pubmed" id="33737254" target="_blank">33737254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29668955">
<a name="29668955"></a>Card T, Xu J, Liang H, Bhayat F. What is the risk of progressive multifocal leukoencephalopathy in patients with ulcerative colitis or Crohn's disease treated with vedolizumab? <i>Inflamm Bowel Dis</i>. 2018;24(5):953-959. doi:10.1093/ibd/izx097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/29668955/pubmed" id="29668955" target="_blank">29668955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chambers.1">
<a name="Chambers.1"></a>Chambers, Christina, PhD, MPH, Adams, Jane, et al. S792 The vedolizumab pregnancy exposure registry: an OTIS pregnancy study update. <i>Am J Gastroenterol</i>. 2021;116:S367-S368. https://journals.lww.com/ajg/Fulltext/2021/10001/S792_The_Vedolizumab_Pregnancy_Exposure_Registry_.793.aspx
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26336591">
<a name="26336591"></a>Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK. Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease. <i>Ther Adv Chronic Dis</i>. 2015;6(5):224-233. doi:10.1177/2040622315586970<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/26336591/pubmed" id="26336591" target="_blank">26336591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30635807">
<a name="30635807"></a>Click B, Regueiro M. Managing risks with biologics. <i>Curr Gastroenterol Rep</i>. 2019;21(2):1. doi:10.1007/s11894-019-0669-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/30635807/pubmed" id="30635807" target="_blank">30635807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26893500">
<a name="26893500"></a>Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i>. 2017;66(5):839-851. doi:10.1136/gutjnl-2015-311079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/26893500/pubmed" id="26893500" target="_blank">26893500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33048114">
<a name="33048114"></a>de Freitas LF, Feitosa MR, Féres O, Parra RS. Cutaneous vasculitis associated with vedolizumab in ulcerative colitis. <i>Inflamm Bowel Dis</i>. 2021;27(2):e15-e17. doi:10.1093/ibd/izaa255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/33048114/pubmed" id="33048114" target="_blank">33048114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36404891">
<a name="36404891"></a>De Marco D, Bessissow T, Marcus V, Benmassaoud A. Vedolizumab-associated hypereosinophilia and hepatoxicity. <i>ACG Case Rep J</i>. 2022;9(11):e00905. doi:10.14309/crj.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/36404891/pubmed" id="36404891" target="_blank">36404891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27296941">
<a name="27296941"></a>Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY consortium. <i>Am J Gastroenterol</i>. 2016;111(8):1147-1155. doi:10.1038/ajg.2016.236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/27296941/pubmed" id="27296941" target="_blank">27296941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Entyvio.2">
<a name="Entyvio.2"></a>Entyvio (vedolizumab) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Entyvio.1">
<a name="Entyvio.1"></a>Entyvio (vedolizumab) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28780013">
<a name="28780013"></a>Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. <i>Gastroenterology.</i> 2017;153(3):827-834. doi: 10.1053/j.gastro.2017.07.032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/28780013/pubmed" id="28780013" target="_blank">28780013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32981127">
<a name="32981127"></a>Flanagan E, Gibson PR, Wright EK, et al; PICCOLO Study Group. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. <i>Aliment Pharmacol Ther.</i> 2020;52(10):1551-1562. doi:10.1111/apt.16102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/32981127/pubmed" id="32981127" target="_blank">32981127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35894810">
<a name="35894810"></a>Ghalandari N, Crijns HJMJ, Bergman JEH, et al. Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: a retrospective comparative study in EudraVigilance. <i>Br J Clin Pharmacol</i>. 2022;88(12):5378-5388. doi:10.1111/bcp.15471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/35894810/pubmed" id="35894810" target="_blank">35894810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29614303">
<a name="29614303"></a>Gold SL, Magro C, Scherl E. A unique infusion reaction to vedolizumab in a patient with Crohn's disease. <i>Gastroenterology</i>. 2018;155(4):981-982. doi:10.1053/j.gastro.2018.03.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/29614303/pubmed" id="29614303" target="_blank">29614303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32584703">
<a name="32584703"></a>Gong Z, Wang Y. Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review. <i>JCO Oncol Pract</i>. 2020;16(8):453-461. doi:10.1200/OP.20.00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/32584703/pubmed" id="32584703" target="_blank">32584703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33155638">
<a name="33155638"></a>Honap S, Sticova E, Theocharidou E, et al. Vedolizumab-associated drug-induced liver injury: a case series. <i>Inflamm Bowel Dis</i>. 2021;27(3):e32-e34. doi:10.1093/ibd/izaa286<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/33155638/pubmed" id="33155638" target="_blank">33155638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34472644">
<a name="34472644"></a>Julsgaard M, Baumgart DC, Baunwall SMD, et al; NOVA Study Group. Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study. <i>Aliment Pharmacol Ther</i>. 2021;54(10):1320-1329. doi:10.1111/apt.16593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/34472644/pubmed" id="34472644" target="_blank">34472644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28073891">
<a name="28073891"></a>Julsgaard M, Kjeldsen J, Baumgart DC. Vedolizumab safety in pregnancy and newborn outcomes. <i>Gut</i>. 2017;66(10):1866-1867. doi: 10.1136/gutjnl-2016-313444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/28073891/pubmed" id="28073891" target="_blank">28073891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28988916">
<a name="28988916"></a>Julsgaard M, Kjeldsen J, Bibby BM, Brock B, Baumgart DC. Vedolizumab concentrations in the breast milk of nursing mothers with inflammatory bowel disease. <i>Gastroenterology</i>. 2018;154(3):752-754.e1. doi: 10.1053/j.gastro.2017.08.067.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/28988916/pubmed" id="28988916" target="_blank">28988916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33387667">
<a name="33387667"></a>Kirchgesner J, Desai RJ, Beaugerie L, Schneeweiss S, Kim SC. Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease. <i>Clin Gastroenterol Hepatol</i>. 2022;20(2):314-324.e16. doi:10.1016/j.cgh.2020.12.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/33387667/pubmed" id="33387667" target="_blank">33387667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28961712">
<a name="28961712"></a>Lahat A, Shitrit AB, Naftali T, et al. Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease. <i>J Crohns Colitis.</i> 2018;12(1):120-123. doi: 10.1093/ecco-jcc/jjx120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/28961712/pubmed" id="28961712" target="_blank">28961712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35949229">
<a name="35949229"></a>Levartovsky A, Yavzori M, Fudim E, Kopylov U, Ben-Horin S, Ungar B. Acute chest pain as an infusion reaction to vedolizumab. <i>Case Rep Gastroenterol</i>. 2022;16(2):430-434. doi:10.1159/000525404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/35949229/pubmed" id="35949229" target="_blank">35949229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. <i>Am J Gastroenterol</i>. 2018;113(4):481-517.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32876349">
<a name="32876349"></a>Loftus EV Jr, Feagan BG, Panaccione R, et al. Long-term safety of vedolizumab for inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2020;52(8):1353-1365. doi:10.1111/apt.16060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/32876349/pubmed" id="32876349" target="_blank">32876349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33470695">
<a name="33470695"></a>Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. <i>Eur J Gastroenterol Hepatol</i>. 2021;33(5):623-630. doi:10.1097/MEG.0000000000002076<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/33470695/pubmed" id="33470695" target="_blank">33470695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33227283">
<a name="33227283"></a>Mahadevan U, Long MD, Kane SV, et al; Crohn's Colitis Foundation Clinical Research Alliance. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. <i>Gastroenterology</i>. 2021;160(4):1131-1139. doi:10.1053/j.gastro.2020.11.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/33227283/pubmed" id="33227283" target="_blank">33227283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30948039">
<a name="30948039"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. <i>Am J Obstet Gynecol</i>. 2019;220(4):308-323. doi: 10.1016/j.ajog.2019.02.027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/30948039/pubmed" id="30948039" target="_blank">30948039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28169436">
<a name="28169436"></a>Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2017;45(7):941-950. doi: 10.1111/apt.13960.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/28169436/pubmed" id="28169436" target="_blank">28169436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34901448">
<a name="34901448"></a>Mascarenhas Saraiva M, Ribeiro T, Dias E, Lopes JL, Cardoso H, Macedo G. Vedolizumab-induced liver injury. <i>GE Port J Gastroenterol</i>. 2020;28(6):410-415. doi:10.1159/000511644<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/34901448/pubmed" id="34901448" target="_blank">34901448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17100965">
<a name="17100965"></a>Mendes FD, Levy C, Enders FB, Loftus EV Jr, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. <i>Am J Gastroenterol</i>. 2007;102(2):344-350. doi:10.1111/j.1572-0241.2006.00947.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/17100965/pubmed" id="17100965" target="_blank">17100965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34394725">
<a name="34394725"></a>Mitrova K, Pipek B, Bortlik M, et al. Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study. <i>Therap Adv Gastroenterol</i>. 2021;14:17562848211032790. doi: 10.1177/17562848211032790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/34394725/pubmed" id="34394725" target="_blank">34394725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35708729">
<a name="35708729"></a>Mitrova K, Pipek B, Bortlik M, et al; Czech IBD Working Group. Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study. <i>J Crohns Colitis</i>. 2022;16(12):1808-1815. doi:10.1093/ecco-jcc/jjac086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/35708729/pubmed" id="35708729" target="_blank">35708729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30281093">
<a name="30281093"></a>Moens A, van Hoeve K, Humblet E, et al; Belgian IBD Research and Development group (BIRD). Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab. <i>J Crohns Colitis.</i> 2019;13(1):12-18. doi: 10.1093/ecco-jcc/jjy142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/30281093/pubmed" id="30281093" target="_blank">30281093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31692017">
<a name="31692017"></a>Moens A, van der Woude CJ, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. <i>Aliment Pharmacol Ther.</i> 2020;51(1):129-138. doi:10.1111/apt.15539<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/31692017/pubmed" id="31692017" target="_blank">31692017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29737503">
<a name="29737503"></a>Parikh A, Stephens K, Major E, et al. A programme for risk assessment and minimisation of progressive multifocal leukoencephalopathy developed for vedolizumab clinical trials. <i>Drug Saf</i>. 2018;41(8):807-816. doi:10.1007/s40264-018-0669-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/29737503/pubmed" id="29737503" target="_blank">29737503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32496114">
<a name="32496114"></a>Pereira Guedes T, Pedroto I, Lago P. Vedolizumab-associated psoriasis: until where does gut selectivity go? <i>Rev Esp Enferm Dig</i>. 2020;112(7):580-581. doi:10.17235/reed.2020.6817/2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/32496114/pubmed" id="32496114" target="_blank">32496114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30643992">
<a name="30643992"></a>Puchner A, Gröchenig HP, Sautner J, et al. Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation. <i>Wien Klin Wochenschr.</i> 2019;131(1-2):29-44. doi: 10.1007/s00508-019-1448-y.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/30643992/pubmed" id="30643992" target="_blank">30643992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30840605">
<a name="30840605"></a>Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. <i>Am J Gastroenterol</i>. 2019;114(3):384-413.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/30840605/pubmed" id="30840605" target="_blank">30840605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27993997">
<a name="27993997"></a>Sheridan J, Cullen G, Doherty G. Letter: vedolizumab in pregnancy. <i>J Crohns Colitis</i>. 2017;11(8):1025-1026. doi:10.1093/ecco-jcc/jjw214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/27993997/pubmed" id="27993997" target="_blank">27993997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35944832">
<a name="35944832"></a>Solitano V, Facciorusso A, Jess T, et al. Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2023;21(4):907-921.e2. doi:10.1016/j.cgh.2022.07.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/35944832/pubmed" id="35944832" target="_blank">35944832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sun.2020">
<a name="Sun.2020"></a>Sun W, Fennimore B, Beaulieu DB, et al. Vedolizumab levels in breast milk: results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease. <i>J Crohns Colitis.</i> 2020;14:S442. doi:10.1093/ecco-jcc/jjz203.638</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30346529">
<a name="30346529"></a>Weizman AV, Nguyen GC, Seow CH, et al. Appropriateness of biologics in the management of crohn's disease using RAND/UCLA appropriateness methodology. <i>Inflamm Bowel Dis.</i> 2019;25(2):328-335. doi: 10.1093/ibd/izy333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/30346529/pubmed" id="30346529" target="_blank">30346529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33345331">
<a name="33345331"></a>Wils P, Seksik P, Stefanescu C, et al; PREGNANCY-GETAID study group. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. <i>Aliment Pharmacol Ther</i>. 2021;53(4):460-470. doi:10.1111/apt.16192<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/33345331/pubmed" id="33345331" target="_blank">33345331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35134937">
<a name="35134937"></a>Xie Y, Li H, Zhou L, Tian F. A case of vedolizumab-induced acute allergic reaction in a patient with refractory ulcerative colitis. <i>Inflamm Bowel Dis</i>. 2022;28(7):e103. doi:10.1093/ibd/izac008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/35134937/pubmed" id="35134937" target="_blank">35134937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34789551">
<a name="34789551"></a>Zou F, Faleck D, Thomas A, et al. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. <i>J Immunother Cancer</i>. 2021;9(11):e003277. doi:10.1136/jitc-2021-003277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/34789551/pubmed" id="34789551" target="_blank">34789551</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 95501 Version 192.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
